<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150981</url>
  </required_header>
  <id_info>
    <org_study_id>12196</org_study_id>
    <nct_id>NCT01150981</nct_id>
  </id_info>
  <brief_title>Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue</brief_title>
  <acronym>RAPA</acronym>
  <official_title>Effect of Rosiglitazone on In-vivo Angiogenic Potential of Human Adipose Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance is a common condition that can lead to type 2 diabetes. One of the
      commonly prescribed diabetes medications, called rosiglitazone, works by decreasing insulin
      resistance. Rosiglitazone appears to work on fat cells. Animal studies suggest that
      rosiglitazone may work by increasing blood vessel growth in fat cells. The purpose of this
      research is to see if rosiglitazone also increases blood vessel growth in human fat cells.
      The investigators will compare results from before and after being on rosiglitazone for 6
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipocytes play a crucial role in the control of metabolic homeostasis, by sequestering
      excess calories in the form of triglycerides, and secreting cytokines that control systemic
      fuel utilization. Sustained excess calorie consumption results in adipocyte hypertrophy and
      hyperplasia, and like any expanding tissue, requires increased capillary expansion to nourish
      the enlarged adipose tissue mass. Recent reports indicate that decreased capillary density in
      adipose tissue of obese individuals correlates with insulin resistance, suggesting that an
      imbalance of angiogenesis and adipogenesis may underlie this condition. To determine whether
      improvement in insulin sensitivity is related to changes in adipose tissue capillary
      development, we conducted a randomized, double-blind, placebo-controlled trial to determine
      capillary density, angiogenic growth potential, and metabolic parameters in healthy human
      volunteers before and after treatment with rosiglitazone, a potent insulin sensitizer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adipose Tissue Capillary Sprout Formation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adipose tissue collected at 8 weeks was cut into ~1mm pieces which were embedded in individual wells of a 96 well plate containing growth factor depleted Matrigel. Wells were filled with media supplemented with endothelial growth factors, replaced every second day. Values for each patient are expressed as the difference in the average number of capillary branches (sprouts) formed by each of approximately 50 explants between day 14 and day 7. The number of branches forming on the periphery (defined as at least three cells in a branch structure) was counted by two investigators at day 7 and 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Adiponectin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adiponectin concentrations in serum were measured in ng/ml, in both arms at baseline and at 8 weeks, i.e. 2 weeks after stopping drug or placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 8mg capsule daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule daily for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>One 8mg capsule daily for 6 weeks.</description>
    <arm_group_label>Rosiglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One capsule daily for 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Overweight but otherwise in good general health.

          2. Age 18 - 55 years.

          3. Normal glucose tolerance.

          4. Stable weight with BMI (27-44).

          5. Stable medication use for the preceding month.

          6. BP &lt; 150/90.

          7. Negative pregnancy test (*HCG), if female and of childbearing potential.

          8. Practicing, and willing to continue to practice appropriate contraception throughout
             the study if a female of childbearing potential.

        Exclusion Criteria:

          1. Serious medical illness.

          2. Pregnancy.

          3. Tobacco use within the past 6 months.

          4. Prior or current treatment with a thiazolidinedione.

          5. Patients who have received an investigational drug in the past 30 days.

          6. Use of systemic corticosteroids.

          7. Known or suspected allergy to Rosiglitazone or any component of the preparation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir Malkani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Worcester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Corvera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMass Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2010</study_first_posted>
  <results_first_submitted>December 16, 2011</results_first_submitted>
  <results_first_submitted_qc>February 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2012</results_first_posted>
  <last_update_submitted>February 25, 2012</last_update_submitted>
  <last_update_submitted_qc>February 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>Samir Malkani</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>dates of recruitment January 2007 to January 2010</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosiglitazone</title>
          <description>One 8mg capsule daily for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>One capsule daily for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosiglitazone</title>
          <description>One 8mg capsule daily for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>One capsule daily for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.25" spread="2.42"/>
                    <measurement group_id="B2" value="40.2" spread="10.23"/>
                    <measurement group_id="B3" value="40.09" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adipose Tissue Capillary Sprout Formation</title>
        <description>Adipose tissue collected at 8 weeks was cut into ~1mm pieces which were embedded in individual wells of a 96 well plate containing growth factor depleted Matrigel. Wells were filled with media supplemented with endothelial growth factors, replaced every second day. Values for each patient are expressed as the difference in the average number of capillary branches (sprouts) formed by each of approximately 50 explants between day 14 and day 7. The number of branches forming on the periphery (defined as at least three cells in a branch structure) was counted by two investigators at day 7 and 14.</description>
        <time_frame>8 weeks</time_frame>
        <population>The number of subjects was based on the power of calculations in being able to demonstrate a difference from baseline in fat tissue microvasculature, change in HOMA2 and serum adiponectin after 6 weeks of rosiglitazone intake in all groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>One 8mg capsule daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One capsule daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adipose Tissue Capillary Sprout Formation</title>
          <description>Adipose tissue collected at 8 weeks was cut into ~1mm pieces which were embedded in individual wells of a 96 well plate containing growth factor depleted Matrigel. Wells were filled with media supplemented with endothelial growth factors, replaced every second day. Values for each patient are expressed as the difference in the average number of capillary branches (sprouts) formed by each of approximately 50 explants between day 14 and day 7. The number of branches forming on the periphery (defined as at least three cells in a branch structure) was counted by two investigators at day 7 and 14.</description>
          <population>The number of subjects was based on the power of calculations in being able to demonstrate a difference from baseline in fat tissue microvasculature, change in HOMA2 and serum adiponectin after 6 weeks of rosiglitazone intake in all groups.</population>
          <units>number of capillary sprouts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.5" spread="41.12"/>
                    <measurement group_id="O2" value="122.1" spread="43.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Adiponectin</title>
        <description>Adiponectin concentrations in serum were measured in ng/ml, in both arms at baseline and at 8 weeks, i.e. 2 weeks after stopping drug or placebo treatment</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rosiglitazone</title>
            <description>One 8mg capsule daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One capsule daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Adiponectin</title>
          <description>Adiponectin concentrations in serum were measured in ng/ml, in both arms at baseline and at 8 weeks, i.e. 2 weeks after stopping drug or placebo treatment</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.56" spread="2.89"/>
                    <measurement group_id="O2" value="14.64" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosiglitazone</title>
          <description>One 8mg capsule daily for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>One capsule daily for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir Malkani, MD</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>5088563800</phone>
      <email>samir.malkani@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

